CLOUD – CeMM library of unique drugs
© Markt et al; licensee BioMed Central Ltd. 2012
Published: 1 May 2012
Approved drugs serve as functional probes for analyzing disease-relevant biochemical pathways or are screened against proteins to identify novel medical applications resulting in a repurposing of known drugs. Despite these benefits of approved drugs, it is almost impossible to physically obtain a complete collection. Commercial vendors cover about 50-65% of drugs. Academic efforts such as the Johns Hopkins Clinical Compound Library (JHCCL)  and the NCGC Pharmaceutical collection  are only accessible via collaboration agreements. Thus, an affordable reference drug library obtainable for all screening centers is still missing. Here we report the generation of the CeMM Library of Unique Drugs (CLOUD), a focused collection of 314 systemically bioavailable small molecule drugs. The library was derived from FDA-approved drugs applying data mining and structural clustering techniques. Reduction of approved drugs to a set of systemically available small molecules and clustering based on their activity classes (e.g. dopamine receptor agonist) resulted in 244 compounds. In addition to this representative set of structural and biological space of drugs, CLOUD contains 35 drugs where the biological target is still unknown. Another 35 molecules representing the active forms of CLOUD prodrugs ensure the usability of the library for both biochemical and cell-based assays. Finally, all CLOUD drugs are delivered in a single 384-well plate in concentrations related to their therapeutic plasma levels to make high-throughput screening as comfortable as possible.
- Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ: A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006, 2: 415-416. 10.1038/nchembio806.View ArticleGoogle Scholar
- Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen DT, Austin CP: The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011, 3: 80ps16-10.1126/scitranslmed.3001862.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.